The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive recommendation for the use of Kyprolis (carfilzomib) in combination with Revlimid® (lenalidomide) and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The recommendation was based on results of the Phase III ASPIRE trial which showed that treatment with this combination significantly improved progression-free survival compared to treatment with Revlimid and low-dose dexamethasone alone (26.3 months versus 17.6 months). This follows the recent US Food and Drug Administration (FDA) approval of Kyprolis, Revlimid and dexamethasone in the same setting. A final decision by the European Commission is expected later this year.

Read full article